Ark Surgical is developing and commercializing LapBox™, a proprietary simple-to-use device facilitating contained removal of large internal organs through a laparoscopic incision in a safe and cost effective manner.
Clinical Need
laparoscopic surgeries for the removal of large organs, particularly in gynecology depend on the use of a power morcellator, a device which shreds the large organ, allowing it to be removed from the body via a small incision. Since 2014 there has been a major reduction in the use of power morcellators due to inherent risk of cancerous tissue spreading throughout the surgical cavity.
LapBox™
LapBox™ creates a confined space within the peritoneal cavity that is easily accessible from outside the abdomen. The unique mechanism employed will ensure simple deployment and removal as well as a higher level of safety than provided by other solutions.
- User-friendly, rapid set up, operation and removal
- Designed for both Manual or power morcellation
- Higher level of safety for the patient
Three US patents has been filed covering the unique concept and structure of LapBox.
The Market
Approximately 500,000 laparoscopic procedures annually that include large organ removal are performed in the US alone with the worldwide number estimated at over 1 million procedures. This offers an estimated market potential for the device of over $500M annually. The key procedures that will be initially targeted for the device include: Hysterectomy, Salpingo/Oophorectomy, Ovarian Cystectomy and Myomectomy.
The Team
- Stav Tori, CEO – Experienced medical device professional with 15 years’ experience.
- Abraham Yaari, Co-founder & Medical Director – Specialized in Obstetrics and Gynecology in New York
- Aaron Feldman, Co-founder & Director – Seasoned medical device entrepreneur
- Zohar Gendler, Director – Managing Partner & CEO of NGT 3 VC.
Contact for Investment
- Stav Tori, CEO of ARK SURGICAL Ltd.
NGT3 (Next Generation Technologies ) Incubator
Web: https://ark-surgical.com
Email: [email protected]
